{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:16:48Z","timestamp":1793128608139,"version":"4.5.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Care Beyond Diagnosis","award":["Care Beyond Diagnosis"],"award-info":[{"award-number":["Care Beyond Diagnosis"]}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","award":["Amicus Therapeutics"],"award-info":[{"award-number":["Amicus Therapeutics"]}],"id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011516","name":"Beyond Batten Disease Foundation","doi-asserted-by":"publisher","award":["Beyond Batten Disease Foundation"],"award-info":[{"award-number":["Beyond Batten Disease Foundation"]}],"id":[{"id":"10.13039\/100011516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CLN3 disease, also called Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), or Batten disease, is an ultra\u2011rare, neurodegenerative lysosomal storage disorder generally affecting individuals during the first decade of life. There can be a delay in diagnosis or misdiagnosis due to a lack of awareness, and when the most common presenting symptom of visual loss is attributed to more common conditions affecting vision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a previously published Expert Mapping Tool (EMT) to identify multidisciplinary professionals with diagnostic or clinical management expertise, as well as patient advocates with experience of CLN3 disease. A systematic literature review of published evidence using the Preferred Reporting Items for Systematic Reviews and Meta\u2011Analyses (PRISMA) guidance was conducted independently and simultaneously to develop key clinical care statements. Each statement was based on the strength of the evidence. The statements formed the basis of an international modified-Delphi consensus process using a virtual meeting platform (Within3). Experts were asked to agree or disagree with each statement and suggest any changes. Statements that reached a consensus of 75% or over are the guiding statements within this manuscript. The processes and manuscript have been independently assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE II) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2011nine international experts from eight specialities were identified, including a patient advocate. Fifty\u2011three recommendation statements were developed covering eleven domains: General statements, Diagnostics, Clinical Recommendations and Management, Assessments, Social Considerations, Ocular Management, Epilepsy\/Seizures, Nutrition, Respiratory Health, Sleep and Rest, and End-of-Life Care. Consensus was reached after one round of voting for all except three statements. The overall AGREE II score for developing these recommendations was 6.4, where 1 represents the lowest and 7 is the highest quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Currently, there are no comprehensive clinical recommendations for CLN3 disease. These recommendations provide a comprehensive, evidence- and consensus\u2011based tool that can be used by all healthcare professionals involved in the management of CLN3 disease and other similar neurodegenerative conditions. The goal is to address the unmet clinical need for CLN3 disease management and complement other information available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04298-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:12:27Z","timestamp":1773141147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recommendations for the diagnosis and management of cln3 disease (batten disease) using the Delphi consensus methodology"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7867-3710","authenticated-orcid":false,"given":"Jonathan W.","family":"Mink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ahrens-Nicklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Nauheimer","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose\u2011Mary","family":"Boustany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Mole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ostergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Sikorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Treat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineka T.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"11","key":"4298_CR1","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","volume":"1832","author":"A Schulz","year":"2013","unstructured":"Schulz A, Kohlsch\u00fctter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013;1832(11):1801\u20136. https:\/\/doi.org\/10.1016\/j.bbadis.2013.04.008.","journal-title":"Biochim Biophys Acta"},{"key":"4298_CR2","doi-asserted-by":"publisher","unstructured":"Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79(2):183\u2009\u2013\u200991. https:\/\/doi.org\/10.1212\/WNL.0b013e31825f0547","DOI":"10.1212\/WNL.0b013e31825f0547"},{"key":"4298_CR3","doi-asserted-by":"publisher","first-page":"754045","DOI":"10.3389\/fneur.2021.754045","volume":"12","author":"E Gardner","year":"2021","unstructured":"Gardner E, Mole SE. The Genetic Basis of Phenotypic Heterogeneity in the Neuronal Ceroid Lipofuscinoses. Front Neurol. 2021;12:754045. https:\/\/doi.org\/10.3389\/fneur.2021.754045.","journal-title":"Front Neurol"},{"issue":"6","key":"4298_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/156652407781695729","volume":"7","author":"D Rakheja","year":"2007","unstructured":"Rakheja D, Narayan SB, Bennett MJ. Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update. Curr Mol Med. 2007;7(6):603\u20138. https:\/\/doi.org\/10.2174\/156652407781695729.","journal-title":"Curr Mol Med"},{"issue":"11","key":"4298_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.bbadis.2013.02.017","volume":"1832","author":"S von Tetzchner","year":"2013","unstructured":"von Tetzchner S, Fosse P, Elmerskog B. Juvenile neuronal ceroid lipofuscinosis and education. Biochim Biophys Acta. 2013;1832(11):1894\u2013905. https:\/\/doi.org\/10.1016\/j.bbadis.2013.02.017.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4298_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10545-010-9163-x","volume":"33","author":"MSMSR Perez Poyato","year":"2010","unstructured":"Perez Poyato MSMSR. The natural history and genotype - phenotype correlations in spanish patients with juvenile neuronal ceroid lipofuscinosis. J Inherit Metab Dis. 2010;33(1):1\u2013197. https:\/\/doi.org\/10.1007\/s10545-010-9163-x.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4298_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/aos.14630","volume":"99","author":"WFE Kuper","year":"2021","unstructured":"Kuper WFE, Talsma HE, van Schooneveld MJ, Pott JWR, Huijgen BCH, de Wit GC, et al. Recognizing differentiating clinical signs of CLN3 disease (Batten disease) at presentation. Acta Ophthalmol. 2021;99(4):397\u2013404. https:\/\/doi.org\/10.1111\/aos.14630.","journal-title":"Acta Ophthalmol"},{"key":"4298_CR8","doi-asserted-by":"publisher","unstructured":"Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852: (10 Pt B) 2237\u201341. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.011. PMC4567481.","DOI":"10.1016\/j.bbadis.2015.05.011"},{"issue":"2","key":"4298_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1086\/514846","volume":"61","author":"PB Munroe","year":"1997","unstructured":"Munroe PB, Mitchison HM, O\u2019Rawe AM, Anderson JW, Boustany RM, Lerner TJ, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet. 1997;61(2):310\u20136. https:\/\/doi.org\/10.1086\/514846.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"4298_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/hmg\/ddm306","volume":"17","author":"C Kitzm\u00fcller","year":"2008","unstructured":"Kitzm\u00fcller C, Haines RL, Codlin S, Cutler DF, Mole SE. A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Hum Mol Genet. 2008;17(2):303\u201312. https:\/\/doi.org\/10.1093\/hmg\/ddm306.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"4298_CR11","doi-asserted-by":"publisher","first-page":"14198","DOI":"10.1038\/s41598-021-93446-8","volume":"11","author":"CJ Minnis","year":"2021","unstructured":"Minnis CJ, Townsend S, Petschnigg J, Tinelli E, B\u00e4hler J, Russell C, et al. Author Correction: Global network analysis in Schizosaccharomyces pombe reveals three distinct consequences of the common 1-kb deletion causing juvenile CLN3 disease. Sci Rep. 2021;11(1):14198. https:\/\/doi.org\/10.1038\/s41598-021-93446-8.","journal-title":"Sci Rep"},{"issue":"11\u201312","key":"4298_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2119\/molmed.2010.00241","volume":"17","author":"AH Lebrun","year":"2011","unstructured":"Lebrun AH, Moll-Khosrawi P, Pohl S, Makrypidi G, Storch S, Kilian D, et al. Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease. Mol Med. 2011;17(11\u201312):1253\u201361. https:\/\/doi.org\/10.2119\/molmed.2010.00241.","journal-title":"Mol Med"},{"issue":"1","key":"4298_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/clp.11.70","volume":"7","author":"SL Cotman","year":"2012","unstructured":"Cotman SL, Staropoli JF. The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking. Clin Lipidol. 2012;7(1):79\u201391. https:\/\/doi.org\/10.2217\/clp.11.70.","journal-title":"Clin Lipidol"},{"key":"4298_CR14","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.bbadis.2015.04.027","volume":"1852","author":"J C\u00e1rcel-Trullols","year":"2015","unstructured":"C\u00e1rcel-Trullols J, Kov\u00e1cs AD, Pearce DA. Cell biology of the NCL proteins: What they do and don\u2019t do. Biochim Biophys Acta. 2015;1852:2242\u201355. https:\/\/doi.org\/10.1016\/j.bbadis.2015.04.027. (10 Pt B).","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"4298_CR15","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1136\/adc.2010.186338.17","volume":"95","author":"AM Winstone","year":"2010","unstructured":"Winstone AM, Verity CM, Stellitano L. The clinical presentation and diagnosis of juvenile neuronal ceroid lipofuscinosis: a prospective national study. Arch Dis Child. 2010;95(Suppl 1):A8. https:\/\/doi.org\/10.1136\/adc.2010.186338.17.","journal-title":"Arch Dis Child"},{"issue":"4","key":"4298_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.oret.2019.11.005","volume":"4","author":"GA Wright","year":"2020","unstructured":"Wright GA, Georgiou M, Robson AG, Ali N, Kalhoro A, Holthaus SK, et al. Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy. Ophthalmol Retina. 2020;4(4):433\u201345. https:\/\/doi.org\/10.1016\/j.oret.2019.11.005.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"4298_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ddrr.1118","volume":"17","author":"MJ Bennett","year":"2013","unstructured":"Bennett MJ, Rakheja D. The neuronal ceroid-lipofuscinoses. Dev Disabil Res Rev. 2013;17(3):254\u20139. https:\/\/doi.org\/10.1002\/ddrr.1118.","journal-title":"Dev Disabil Res Rev"},{"issue":"4","key":"4298_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/13816810.2014.886271","volume":"36","author":"AV Drack","year":"2015","unstructured":"Drack AV, Mullins RF, Pfeifer WL, Augustine EF, Stasheff SF, Hong SD. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease). Ophthalmic Genet. 2015;36(4):359\u201364. https:\/\/doi.org\/10.3109\/13816810.2014.886271.","journal-title":"Ophthalmic Genet"},{"issue":"7","key":"4298_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1469-8749.2010.03628.x.PMC2895016","volume":"52","author":"HR Adams","year":"2010","unstructured":"Adams HR, Beck CA, Levy E, Jordan R, Kwon JM, Marshall FJ, et al. Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Dev Med Child Neurol. 2010;52(7):637\u201343. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03628.x.","journal-title":"Dev Med Child Neurol"},{"key":"4298_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/dnnd.S111967","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73\u201383. https:\/\/doi.org\/10.2147\/dnnd.S111967. PMC6053093.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"2","key":"4298_CR21","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1016\/j.ymgme.2019.11.444","volume":"129","author":"G Zimmerman","year":"2020","unstructured":"Zimmerman G, Vierhile A, Adams H, Mink J, Augustine E. Methods for quantitative gait analysis in CLN3 disease. Mol Genet Metab. 2020;129(2):S166. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.444.","journal-title":"Mol Genet Metab"},{"key":"4298_CR22","doi-asserted-by":"publisher","unstructured":"Whiteman IT, CAL, Augustine EF, Bindhoff AD, Johnson AM, Mason HL, Mink JW, \u00d8stergaard JR, Schulz A, Vermillion J, Vierhile A, Adams HR. A timeline of symptom onset and disease progression in CLN3 Disease. Orphanet J Rare Dis. 2026;21(1):38. https:\/\/doi.org\/10.1186\/s13023-025-04174-5","DOI":"10.1186\/s13023-025-04174-5"},{"issue":"2","key":"4298_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10545-018-0143-x","volume":"41","author":"WFE Kuper","year":"2018","unstructured":"Kuper WFE, van Alfen C, Rigterink RH, Fuchs SA, van Genderen MM, van Hasselt PM. Timing of cognitive decline in CLN3 disease. J Inherit Metab Dis. 2018;41(2):257\u201361. https:\/\/doi.org\/10.1007\/s10545-018-0143-x.","journal-title":"J Inherit Metab Dis"},{"key":"4298_CR24","doi-asserted-by":"publisher","first-page":"866983","DOI":"10.3389\/fneur.2022.866983","volume":"13","author":"U Bartsch","year":"2022","unstructured":"Bartsch U, Storch S. Experimental Therapeutic Approaches for the Treatment of Retinal Pathology in Neuronal Ceroid Lipofuscinoses. Front Neurol. 2022;13:866983. https:\/\/doi.org\/10.3389\/fneur.2022.866983.","journal-title":"Front Neurol"},{"issue":"1","key":"4298_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Kleine Holthaus SM, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107\u201316. https:\/\/doi.org\/10.1016\/s1474-4422(18)30368-5.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4298_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-021-01813-5.PMC8059011","volume":"16","author":"SE Mole","year":"2021","unstructured":"Mole SE, Schulz A, Badoe E, Berkovic SF, de Los Reyes EC, Dulz S, et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis. 2021;16(1):185. https:\/\/doi.org\/10.1186\/s13023-021-01813-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"4298_CR27","doi-asserted-by":"publisher","first-page":"e000791","DOI":"10.1136\/rmdopen-2018-000791","volume":"4","author":"M Mosca","year":"2018","unstructured":"Mosca M, Cutolo M. Clinical practice guidelines: the first year of activity of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). RMD Open. 2018;4(Suppl 1):e000791. https:\/\/doi.org\/10.1136\/rmdopen-2018-000791. PMC6203103.","journal-title":"RMD Open"},{"key":"4298_CR28","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S1090-3798(15)30402-5","volume":"19","author":"A Schulz","year":"2015","unstructured":"Schulz A, Miller N, Mole SE, Cohen-Pfeffer JL. P89\u20132878: Neuronal ceroid lipofuscinosis-2 (CLN2) natural history and path to diagnosis: International experts\u2019 current experience and recommendations on CLN2 disease, a type of Batten disease, resulting from TPP1 enzyme deficiency. Eur J Pediatr Neurol. 2015;19:S119. https:\/\/doi.org\/10.1016\/S1090-3798(15)30402-5.","journal-title":"Eur J Pediatr Neurol"},{"key":"4298_CR29","doi-asserted-by":"publisher","unstructured":"Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, et al. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015;3(3). https:\/\/doi.org\/10.15190\/d.2015.42.","DOI":"10.15190\/d.2015.42"},{"issue":"2","key":"4298_CR30","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.ymgme.2018.12.170","volume":"126","author":"CJ Hendriksz","year":"2019","unstructured":"Hendriksz CJ, Donohue J, Donohue Y, Mole SE. Methodology to develop guidelines for the management of patients with neuronal ceroid lipofuscinosis type 2 disease. Mol Genet Metab. 2019;126(2):S71. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.170.","journal-title":"Mol Genet Metab"},{"key":"4298_CR31","first-page":"PMC5065023","volume":"17","author":"BC Wallace","year":"2016","unstructured":"Wallace BC, Kuiper J, Sharma A, Zhu MB, Marshall IJ. Extracting PICO Sentences from Clinical Trial Reports using Supervised Distant Supervision. J Mach Learn Res. 2016;17:PMC5065023.","journal-title":"J Mach Learn Res"},{"key":"4298_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inf Decis Mak. 2007;7:16. https:\/\/doi.org\/10.1186\/1472-6947-7-16.","journal-title":"BMC Med Inf Decis Mak"},{"key":"4298_CR33","doi-asserted-by":"publisher","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1): 305\u2009\u2013\u200910. https:\/\/doi.org\/10.1097\/PRS.0b013e318219c171. PMC3124652.","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"4298_CR34","unstructured":"Within3. A complete insights management solution for life science. Within3 [Available from: https:\/\/within3.com\/"},{"key":"4298_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los Reyes E, Denecke J, et al. Management Strategies for CLN2 Disease. Pediatr Neurol. 2017;69:102\u201312. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.01.034.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"4298_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002.","journal-title":"J Clin Epidemiol"},{"key":"4298_CR37","doi-asserted-by":"publisher","first-page":"i1152","DOI":"10.1136\/bmj.i1152","volume":"352","author":"MC Brouwers","year":"2016","unstructured":"Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152. https:\/\/doi.org\/10.1136\/bmj.i1152.","journal-title":"BMJ"},{"issue":"1","key":"4298_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"issue":"2","key":"4298_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00041327-200020020-00010","volume":"20","author":"LI Bohra","year":"2000","unstructured":"Bohra LI, Weizer JS, Lee AG, Lewis RA. Vision loss as the presenting sign in juvenile neuronal ceroid lipofuscinosis. J Neuroophthalmol. 2000;20(2):111\u20135. https:\/\/doi.org\/10.1097\/00041327-200020020-00010.","journal-title":"J Neuroophthalmol"},{"key":"4298_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2021.09.004","volume":"35","author":"JR Ostergaard","year":"2021","unstructured":"Ostergaard JR. Gait phenotype in Batten disease: A marker of disease progression. Eur J Paediatr Neurol. 2021;35:1\u20137. https:\/\/doi.org\/10.1016\/j.ejpn.2021.09.004.","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"4298_CR41","doi-asserted-by":"publisher","first-page":"165480","DOI":"10.1016\/j.bbadis.2019.05.016","volume":"1866","author":"B Elmerskog","year":"2020","unstructured":"Elmerskog B, T\u00f8ssebro AG, Atkinson R, Rokne S, Cole B, Ockelford A, et al. Overview of advances in educational and social supports for young persons with NCL disorders. Biochim Biophys Acta Mol Basis Dis. 2020;1866(9):165480. https:\/\/doi.org\/10.1016\/j.bbadis.2019.05.016.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"4298_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dmcn.12634","volume":"57","author":"EF Augustine","year":"2015","unstructured":"Augustine EF, Adams HR, Beck CA, Vierhile A, Kwon J, Rothberg PG, et al. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2015;57(4):366\u201371. https:\/\/doi.org\/10.1111\/dmcn.12634.","journal-title":"Dev Med Child Neurol"},{"key":"4298_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autneu.2018.07.003","volume":"214","author":"JR Ostergaard","year":"2018","unstructured":"Ostergaard JR. Paroxysmal sympathetic hyperactivity in Juvenile neuronal ceroid lipofuscinosis (Batten disease). Auton Neurosci. 2018;214:15\u20138. https:\/\/doi.org\/10.1016\/j.autneu.2018.07.003.","journal-title":"Auton Neurosci"},{"key":"4298_CR44","doi-asserted-by":"publisher","first-page":"1059082","DOI":"10.3389\/fpsyt.2023.1059082","volume":"14","author":"JR Ostergaard","year":"2023","unstructured":"Ostergaard JR. Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Front Psychiatry. 2023;14:1059082. https:\/\/doi.org\/10.3389\/fpsyt.2023.1059082.","journal-title":"Front Psychiatry"},{"issue":"2","key":"4298_CR45","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ymgme.2012.11.170","volume":"108","author":"J Mink","year":"2013","unstructured":"Mink J, Augustine EF, Marshall FJ, Adams HR, Kwon JM, Vierhile A, et al. The natural history of juvenile Batten disease (JNCL; CLN3 disease). Mol Genet Metab. 2013;108(2):S66. https:\/\/doi.org\/10.1016\/j.ymgme.2012.11.170.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4298_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpn.2012.10.011","volume":"17","author":"AK Nielsen","year":"2013","unstructured":"Nielsen AK, \u00d8stergaard JR. Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience. Eur J Paediatr Neurol. 2013;17(3):265\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2012.10.011.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"4298_CR47","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.ymgme.2020.12.160","volume":"132","author":"MC Masten","year":"2021","unstructured":"Masten MC, Vierhile A, Vermilion J, Adams HR, Augustine EF, Mink JW. Genotype-phenotype associations in CLN3 disease. Mol Genet Metab. 2021;132(2):S69\u201370. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.160.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR48","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/wnl.52.2.360","volume":"52","author":"L Lauronen","year":"1999","unstructured":"Lauronen L, Munroe PB, J\u00e4rvel\u00e4 I, Autti T, Mitchison HM, O\u2019Rawe AM, et al. Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis. Neurology. 1999;52(2):360\u20135. https:\/\/doi.org\/10.1212\/wnl.52.2.360.","journal-title":"Neurology"},{"issue":"3","key":"4298_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s13760-021-01655-9","volume":"121","author":"N Gilani","year":"2021","unstructured":"Gilani N, Razmara E, Ozaslan M, Abdulzahra IK, Arzhang S, Tavasoli AR, et al. A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses. Acta Neurol Belg. 2021;121(3):737\u201348. https:\/\/doi.org\/10.1007\/s13760-021-01655-9.","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"4298_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","volume":"6","author":"SE Mole","year":"2005","unstructured":"Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6(3):107\u201326. https:\/\/doi.org\/10.1007\/s10048-005-0218-3.","journal-title":"Neurogenetics"},{"issue":"5","key":"4298_CR51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10545-011-9323-7","volume":"34","author":"MS P\u00e9rez-Poyato","year":"2011","unstructured":"P\u00e9rez-Poyato MS, Mil\u00e0 Recansens M, Ferrer Abizanda I, Montero S\u00e1nchez R, Rodr\u00edguez-Revenga L, Cus\u00ed S\u00e1nchez V, et al. Juvenile neuronal ceroid lipofuscinosis: clinical course and genetic studies in Spanish patients. J Inherit Metab Dis. 2011;34(5):1083\u201393. https:\/\/doi.org\/10.1007\/s10545-011-9323-7.","journal-title":"J Inherit Metab Dis"},{"issue":"20","key":"4298_CR52","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1212\/WNL.0b013e318237f649","volume":"77","author":"JM Kwon","year":"2011","unstructured":"Kwon JM, Adams H, Rothberg PG, Augustine EF, Marshall FJ, Deblieck EA, et al. Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011;77(20):1801\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e318237f649. PMC3233207.","journal-title":"Neurology"},{"issue":"02","key":"4298_CR53","doi-asserted-by":"publisher","first-page":"V1264","DOI":"10.1055\/s-0030-1265526","volume":"41","author":"A Schulz","year":"2010","unstructured":"Schulz A, Moll-Khosrawi P, Kilian D, Braulke T, Kohlsch\u00fctter A. High phenotype variability in CLN3 patients with identical genotype. Neuropediatrics. 2010;41(02):V1264. https:\/\/doi.org\/10.1055\/s-0030-1265526.","journal-title":"Neuropediatrics"},{"key":"4298_CR54","doi-asserted-by":"publisher","unstructured":"Lee TS, Poon SH, Chang P. Dissimilar neuropsychiatric presentations of two siblings with juvenile neuronal ceroid lipofuscinosis (Batten disease). J Neuropsychiatry Clin Neurosci. 2010;22(1):123.E14-5. https:\/\/doi.org\/10.1176\/jnp.2010.22.1.123.e14","DOI":"10.1176\/jnp.2010.22.1.123.e14"},{"key":"4298_CR55","unstructured":"UCL (London U. NCL Resource - A gateway for Batten disease University College London2023 [NCL resource webpage]. Available from: https:\/\/www.ucl.ac.uk\/ncl-disease"},{"key":"4298_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/978-1-4614-0653-2_11","volume":"724","author":"S Wang","year":"2012","unstructured":"Wang S. Juvenile neuronal ceroid lipofuscinoses. Adv Exp Med Biol. 2012;724:138\u201342. https:\/\/doi.org\/10.1007\/978-1-4614-0653-2_11.","journal-title":"Adv Exp Med Biol"},{"key":"4298_CR57","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/bjo.2006.091637","volume":"90","author":"J Collins","year":"2006","unstructured":"Collins J, Holder GE, Herbert H, Adams GG. Batten disease: features to facilitate early diagnosis. Br J Ophthalmol. 2006;90:1119\u201324. https:\/\/doi.org\/10.1136\/bjo.2006.091637.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"4298_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/01.Jaa.0000750980.85777.01","volume":"34","author":"K Niederer","year":"2021","unstructured":"Niederer K. Juvenile Batten disease: A diagnostic conundrum. Jaapa. 2021;34(6):44\u20137. https:\/\/doi.org\/10.1097\/01.Jaa.0000750980.85777.01.","journal-title":"Jaapa"},{"issue":"4","key":"4298_CR59","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/dmcn.14346","volume":"62","author":"B Dozi\u00e8res-Puyravel","year":"2020","unstructured":"Dozi\u00e8res-Puyravel B, Nasser H, Elmaleh-Berg\u00e8s M, Lopez Hernandez E, Gelot A, Ilea A, et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol. 2020;62(4):528\u201330. https:\/\/doi.org\/10.1111\/dmcn.14346.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"4298_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13023-022-02358-x","volume":"17","author":"A Bauskis","year":"2022","unstructured":"Bauskis A, Strange C, Molster C, Fisher C. The diagnostic odyssey: insights from parents of children living with an undiagnosed condition. Orphanet J Rare Dis. 2022;17(1):233. https:\/\/doi.org\/10.1186\/s13023-022-02358-x.","journal-title":"Orphanet J Rare Dis"},{"key":"4298_CR61","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.bbadis.2015.05.003","volume":"1852","author":"R Kohan","year":"2015","unstructured":"Kohan R, Pesaola F, Guelbert N, Pons P, Oller-Ram\u00edrez AM, Rautenberg G, et al. The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina. Biochim Biophys Acta. 2015;1852:2301\u201311. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.003. (10 Pt B).","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"4298_CR62","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/jimd.12429","volume":"44","author":"MC Masten","year":"2021","unstructured":"Masten MC, Corre C, Paciorkowski AR, Vierhile A, Adams HR, Vermilion J, et al. A diagnostic confidence scheme for CLN3 disease. J Inherit Metab Dis. 2021;44(6):1453\u201362. https:\/\/doi.org\/10.1002\/jimd.12429.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"4298_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/019131201300004681","volume":"25","author":"R Boldrini","year":"2001","unstructured":"Boldrini R, Biselli R, Santorelli FM, Bosman C. Neuronal ceroid lipofuscinosis: an ultrastructural, genetic, and clinical study report. Ultrastruct Pathol. 2001;25(1):51\u20138. https:\/\/doi.org\/10.1080\/019131201300004681.","journal-title":"Ultrastruct Pathol"},{"issue":"9","key":"4298_CR64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/bf02762187","volume":"67","author":"S Gulati","year":"2000","unstructured":"Gulati S, Maheshwari R, Kabra M, Verma IC, Kalra V. Juvenile neuronal ceroid lipofuscinosis. Indian J Pediatr. 2000;67(9):689\u201391. https:\/\/doi.org\/10.1007\/bf02762187.","journal-title":"Indian J Pediatr"},{"issue":"11","key":"4298_CR65","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/acn3.662","volume":"5","author":"J Radke","year":"2018","unstructured":"Radke J, Koll R, Gill E, Wiese L, Schulz A, Kohlsch\u00fctter A, et al. Autophagic vacuolar myopathy is a common feature of CLN3 disease. Ann Clin Transl Neurol. 2018;5(11):1385\u201393. https:\/\/doi.org\/10.1002\/acn3.662.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"4298_CR66","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/jcp.2005.027045","volume":"58","author":"G Anderson","year":"2005","unstructured":"Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58(12):1305\u201310. https:\/\/doi.org\/10.1136\/jcp.2005.027045.","journal-title":"J Clin Pathol"},{"issue":"3a","key":"4298_CR67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1590\/s0004-282x2000000400001","volume":"58","author":"AC Puga","year":"2000","unstructured":"Puga AC, Jardim LB, Chimelli L, De Souza CF, Clivati M. Neuronal ceroid lipofuscinoses: a clinical and morphological study of 17 patients from southern Brazil. Arq Neuropsiquiatr. 2000;58(3a):597\u2013606. https:\/\/doi.org\/10.1590\/s0004-282x2000000400001.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"4298_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jmd2.12128","volume":"54","author":"WFE Kuper","year":"2020","unstructured":"Kuper WFE, Oostendorp M, van den Broek BTA, van Veghel K, Nonkes LJP, Nieuwenhuis EES, et al. Quantifying lymphocyte vacuolization serves as a measure of CLN3 disease severity. JIMD Rep. 2020;54(1):87\u201397. https:\/\/doi.org\/10.1002\/jmd2.12128.","journal-title":"JIMD Rep"},{"issue":"5","key":"4298_CR69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ana.410420517","volume":"42","author":"I J\u00e4rvel\u00e4","year":"1997","unstructured":"J\u00e4rvel\u00e4 I, Autti T, Lamminranta S, Aberg L, Raininko R, Santavuori P. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02-kb deletion). Ann Neurol. 1997;42(5):799\u2013802. https:\/\/doi.org\/10.1002\/ana.410420517.","journal-title":"Ann Neurol"},{"issue":"5","key":"4298_CR70","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-2004-812819","volume":"221","author":"I Mantel","year":"2004","unstructured":"Mantel I, Brantley MA Jr., Bellmann C, Robson AG, Holder GE, Taylor A, et al. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence. Klin Monbl Augenheilkd. 2004;221(5):427\u201330. https:\/\/doi.org\/10.1055\/s-2004-812819.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"3","key":"4298_CR71","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10633-023-09930-1","volume":"146","author":"DH Sakti","year":"2023","unstructured":"Sakti DH, Cornish EE, Fraser CL, Nash BM, Sandercoe TM, Jones MM, et al. Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging. Doc Ophthalmol. 2023;146(3):241\u201356. https:\/\/doi.org\/10.1007\/s10633-023-09930-1.","journal-title":"Doc Ophthalmol"},{"key":"4298_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10633-016-9548-8","volume":"133","author":"RB Hamilton","year":"2016","unstructured":"Hamilton RB, Horrocks A, MacLeod IA, Morris S, O\u2019Regan W, Spowart ME, Yeo K, Zuberi TH, S.M. Sensitivity and specificity of the light-adapted ERG in suspected neuronal ceroid lipofuscinosis (NCLs). Doc Ophthalmol. 2016;133:9\u201341. https:\/\/doi.org\/10.1007\/s10633-016-9548-8.","journal-title":"Doc Ophthalmol"},{"issue":"8","key":"4298_CR73","doi-asserted-by":"publisher","first-page":"e1308","DOI":"10.1002\/mgg3.1308","volume":"8","author":"K Mizobuchi","year":"2020","unstructured":"Mizobuchi K, Hayashi T, Yoshitake K, Fujinami K, Tachibana T, Tsunoda K, et al. Novel homozygous CLN3 missense variant in isolated retinal dystrophy: A case report and electron microscopic findings. Mol Genet Genomic Med. 2020;8(8):e1308. https:\/\/doi.org\/10.1002\/mgg3.1308.","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"4298_CR74","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/nyas.12990","volume":"1371","author":"MM Ouseph","year":"2016","unstructured":"Ouseph MM, Kleinman ME, Wang QJ. Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Ann N Y Acad Sci. 2016;1371(1):55\u201367. https:\/\/doi.org\/10.1111\/nyas.12990.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"4298_CR75","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamaophthalmol.2017.4353","volume":"135","author":"WFE Kuper","year":"2017","unstructured":"Kuper WFE, van Alfen C, van Eck L, van den Broek BTA, Huisman A, van Genderen MM, et al. A Case of Unexpected Adult-Onset Neurologic Decline in CLN3-Associated Retinal Degeneration. JAMA Ophthalmol. 2017;135(12):1451\u20133. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4353.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"4298_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10633-018-9665-7","volume":"138","author":"FK Chen","year":"2019","unstructured":"Chen FK, Zhang X, Eintracht J, Zhang D, Arunachalam S, Thompson JA, et al. Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G\u2009>\u2009A mutation in ceroid lipofuscinosis neuronal 3 (CLN3). Doc Ophthalmol. 2019;138(1):55\u201370. https:\/\/doi.org\/10.1007\/s10633-018-9665-7.","journal-title":"Doc Ophthalmol"},{"key":"4298_CR77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ceo.12650","volume":"43","author":"TD McLaren","year":"2015","unstructured":"McLaren TD, Chen J, Ruddle F, J., et al. Establishment of compound heterozygous CLN3 mutations in two unrelated patients not presenting with neurodegenerative disease. Clin Experimental Ophthalmol. 2015;43:34\u201356. https:\/\/doi.org\/10.1111\/ceo.12650.","journal-title":"Clin Experimental Ophthalmol"},{"issue":"4","key":"4298_CR78","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.survophthal.2009.04.007","volume":"54","author":"S Bozorg","year":"2009","unstructured":"Bozorg S, Ramirez-Montealegre D, Chung M, Pearce DA. Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye. Surv Ophthalmol. 2009;54(4):463\u201371. https:\/\/doi.org\/10.1016\/j.survophthal.2009.04.007.","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"4298_CR79","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1111\/epi.17616","volume":"64","author":"JM Cameron","year":"2023","unstructured":"Cameron JM, Damiano JA, Grinton B, Carney PW, McKelvie P, Silbert P, et al. Recognition and epileptology of protracted CLN3 disease. Epilepsia. 2023;64(7):1833\u201341. https:\/\/doi.org\/10.1111\/epi.17616.","journal-title":"Epilepsia"},{"issue":"11","key":"4298_CR80","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/jnen\/nlab064","volume":"80","author":"LP Evans","year":"2021","unstructured":"Evans LP, Gibson-Corley KN, Mullins RF, Tucker BA, Trent A, Stone EM, et al. An Unusual Presentation of CLN3-Associated Batten Disease With Classic Histopathologic and Ultrastructural Findings. J Neuropathol Exp Neurol. 2021;80(11):1081\u20134. https:\/\/doi.org\/10.1093\/jnen\/nlab064.","journal-title":"J Neuropathol Exp Neurol"},{"key":"4298_CR81","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1007\/s10545-015-9877-x","volume":"38","author":"MC \u00c7oker","year":"2015","unstructured":"\u00c7oker MC, Kagnici E, K\u00f6se M, Tosun M, Polat A, Kalkan Ucar M S. Cases of neuronal ceroid lipofuscinosis. J Inherit Metab Dis. 2015;38:S370. https:\/\/doi.org\/10.1007\/s10545-015-9877-x.","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"4298_CR82","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ejmg.2015.09.002","volume":"58","author":"L Licchetta","year":"2015","unstructured":"Licchetta L, Bisulli F, Fietz M, Valentino ML, Morbin M, Mostacci B, et al. A novel mutation af Cln3 associated with delayed-classic juvenile ceroid lipofuscinois and autophagic vacuolar myopathy. Eur J Med Genet. 2015;58(10):540\u20134. https:\/\/doi.org\/10.1016\/j.ejmg.2015.09.002.","journal-title":"Eur J Med Genet"},{"issue":"Suppl A","key":"4298_CR83","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1053\/ejpn.2000.0458","volume":"5","author":"A Larsen","year":"2001","unstructured":"Larsen A, Sainio K, Aberg L, Santavuori P. Electroencephalography in juvenile neuronal ceroid lipofuscinosis: visual and quantitative analysis. Eur J Paediatr Neurol. 2001;5(Suppl A):179\u201383. https:\/\/doi.org\/10.1053\/ejpn.2000.0458.","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"4298_CR84","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00234-022-02988-9","volume":"64","author":"JN Hochstein","year":"2022","unstructured":"Hochstein JN, Schulz A, Nickel M, Lezius S, Grosser M, Fiehler J, et al. Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarker. Neuroradiology. 2022;64(10):2059\u201367. https:\/\/doi.org\/10.1007\/s00234-022-02988-9.","journal-title":"Neuroradiology"},{"issue":"6","key":"4298_CR85","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/197140091202500616","volume":"25","author":"RH Jadav","year":"2012","unstructured":"Jadav RH, Sinha S, Yasha TC, Aravinda H, Rao S, Bindu PS, et al. Magnetic resonance imaging in neuronal ceroid lipofuscinosis and its subtypes. Neuroradiol J. 2012;25(6):755\u201361. https:\/\/doi.org\/10.1177\/197140091202500616.","journal-title":"Neuroradiol J"},{"issue":"4","key":"4298_CR86","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1468-1331.2007.01692.x","volume":"14","author":"T Autti","year":"2007","unstructured":"Autti T, H\u00e4m\u00e4l\u00e4inen J, Aberg L, Lauronen L, Tyynel\u00e4 J, Van Leemput K. Thalami and corona radiata in juvenile NCL (CLN3): a voxel-based morphometric study. Eur J Neurol. 2007;14(4):447\u201350. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01692.x.","journal-title":"Eur J Neurol"},{"issue":"8","key":"4298_CR87","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s00415-008-0891-x","volume":"255","author":"TH Autti","year":"2008","unstructured":"Autti TH, H\u00e4m\u00e4l\u00e4inen J, Mannerkoski M, Van Leemput KV, Aberg LE. JNCL patients show marked brain volume alterations on longitudinal MRI in adolescence. J Neurol. 2008;255(8):1226\u201330. https:\/\/doi.org\/10.1007\/s00415-008-0891-x.","journal-title":"J Neurol"},{"issue":"3","key":"4298_CR88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1055\/s-2002-33677","volume":"33","author":"JO Rinne","year":"2002","unstructured":"Rinne JO, Ruottinen HM, N\u00e5gren K, Aberg LE, Santavuori P. Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis. Neuropediatrics. 2002;33(3):138\u201341. https:\/\/doi.org\/10.1055\/s-2002-33677.","journal-title":"Neuropediatrics"},{"issue":"1","key":"4298_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nmd.2018.11.006","volume":"29","author":"F Moro","year":"2019","unstructured":"Moro F, Rubegni A, Pochiero F, Mero S, Procopio E, Baldacci J, et al. Autophagic vacuolar myopathy caused by a CLN3 mutation. A case report. Neuromuscul Disord. 2019;29(1):67\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2018.11.006.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"4298_CR90","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s004010051053","volume":"98","author":"M Villanova","year":"1999","unstructured":"Villanova M, Ceuterick C, Dotti MT, Santorelli FM, Casali C, Malandrini A, et al. Detection of beta-A4 amyloid and its precursor protein in the muscle of a patient with juvenile neuronal ceroid lipofuscinosis (Spielmeyer-Vogt-Sj\u00f6gren). Acta Neuropathol. 1999;98(1):78\u201384. https:\/\/doi.org\/10.1007\/s004010051053.","journal-title":"Acta Neuropathol"},{"issue":"23","key":"4298_CR91","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1212\/wnl.0000000000000490","volume":"82","author":"A Cortese","year":"2014","unstructured":"Cortese A, Tucci A, Piccolo G, Galimberti CA, Fratta P, Marchioni E, et al. Novel CLN3 mutation causing autophagic vacuolar myopathy. Neurology. 2014;82(23):2072\u20136. https:\/\/doi.org\/10.1212\/wnl.0000000000000490.","journal-title":"Neurology"},{"issue":"9","key":"4298_CR92","doi-asserted-by":"publisher","first-page":"165643","DOI":"10.1016\/j.bbadis.2019.165643","volume":"1866","author":"K Rietdorf","year":"2020","unstructured":"Rietdorf K, Coode EE, Schulz A, Wibbeler E, Bootman MD, Ostergaard JR. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity. Biochim Biophys Acta Mol Basis Dis. 2020;1866(9):165643. https:\/\/doi.org\/10.1016\/j.bbadis.2019.165643.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4298_CR93","unstructured":"Willams RE, Kendrick M, Menson S, Griffiths E. R. On behalf of the BDFA professional development group. Juvenile neuronal ceroid lipofuscinosis (Batten disease): what should we tell the children? Developmental Medicine & Child Neurology; 2009. p. 60."},{"issue":"9","key":"4298_CR94","doi-asserted-by":"publisher","first-page":"165773","DOI":"10.1016\/j.bbadis.2020.165773","volume":"1866","author":"H Band","year":"2020","unstructured":"Band H, Stehr F, Murphy N. Contribution of patient organisations to the NCLs. Biochim Biophys Acta Mol Basis Dis. 2020;1866(9):165773. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165773.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"S4","key":"4298_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/dmcn.13623","volume":"59","author":"SAE Good","year":"2017","unstructured":"Good SAE, Adams M, Williams H, R. E. An Exploration of Perceived Quality of Life in Families and Carers of Children with CLN3 Juvenile Batten Disease. Dev Med Child Neurol. 2017;59(S4):39\u2013136. https:\/\/doi.org\/10.1111\/dmcn.13623.","journal-title":"Dev Med Child Neurol"},{"key":"4298_CR96","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10545-010-9163-x","volume":"33","author":"KM Al-Thihli","year":"2010","unstructured":"Al-Thihli KM, Roland C, Sockler-Ipsiroglu E, Mercimek-Mahmuoglu S, S. Juvenile neuronal ceroid lipofuscinosis in a patient with compound heterozygous CLN3 mutations: A 9-year follow-up. J Inherit Metab Dis. 2010;33:S1\u2013197. https:\/\/doi.org\/10.1007\/s10545-010-9163-x.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"4298_CR97","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1212\/01.wnl.0000169019.41332.8a","volume":"65","author":"FJ Marshall","year":"2005","unstructured":"Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65(2):275\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000169019.41332.8a.","journal-title":"Neurology"},{"issue":"6","key":"4298_CR98","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1651-2227.1988.tb10770.x","volume":"77","author":"A Kohlsch\u00fctter","year":"1988","unstructured":"Kohlsch\u00fctter A, Laabs R, Albani M. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability. Acta Paediatr Scand. 1988;77(6):867\u201372. https:\/\/doi.org\/10.1111\/j.1651-2227.1988.tb10770.x.","journal-title":"Acta Paediatr Scand"},{"issue":"5","key":"4298_CR99","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ajmg.a.62114","volume":"185","author":"H Hildenbrand","year":"2021","unstructured":"Hildenbrand H, Wickstrom J, Parks R, Zampieri C, Nguyen TT, Thurm A, et al. Characterizing upper limb function in the context of activities of daily living in CLN3 disease. Am J Med Genet A. 2021;185(5):1399\u2013413. https:\/\/doi.org\/10.1002\/ajmg.a.62114.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"4298_CR100","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00540-020-02747-1","volume":"34","author":"Y Yamaguchi","year":"2020","unstructured":"Yamaguchi Y, Lyman R, De Los Reyes E, Kim SS, Uffman JC, Tobias JD. Batten disease and perioperative complications: a retrospective descriptive study. J Anesth. 2020;34(3):342\u20137. https:\/\/doi.org\/10.1007\/s00540-020-02747-1.","journal-title":"J Anesth"},{"issue":"3","key":"4298_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/eja.0000000000000111","volume":"32","author":"F Richa","year":"2015","unstructured":"Richa F. Anaesthesia and orphan disease: a child with neuronal ceroid lipofuscinosis. Eur J Anaesthesiol. 2015;32(3):213\u20135. https:\/\/doi.org\/10.1097\/eja.0000000000000111.","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"4298_CR102","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(3):549\u201355. https:\/\/doi.org\/10.1007\/s10545-011-9421-6.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4298_CR103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1017\/s0012162206000570","volume":"48","author":"H Adams","year":"2006","unstructured":"Adams H, de Blieck EA, Mink JW, Marshall FJ, Kwon J, Dure L, et al. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48(4):259\u201364. https:\/\/doi.org\/10.1017\/s0012162206000570.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"4298_CR104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/ejpn.2002.0594","volume":"6","author":"LE Aberg","year":"2002","unstructured":"Aberg LE, Tiitinen A, Autti TH, Kivisaari L, Santavouri P. Hyperandrogenism in girls with juvenile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2002;6(4):199\u2013205. https:\/\/doi.org\/10.1053\/ejpn.2002.0594.","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"4298_CR105","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1212\/wnl.56.9.1236","volume":"56","author":"LE Aberg","year":"2001","unstructured":"Aberg LE, Rinne JO, Rajantie I, Santavuori P. A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis. Neurology. 2001;56(9):1236\u20139. https:\/\/doi.org\/10.1212\/wnl.56.9.1236.","journal-title":"Neurology"},{"issue":"5","key":"4298_CR106","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0883073807302603","volume":"22","author":"HR Adams","year":"2007","unstructured":"Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies. J Child Neurol. 2007;22(5):621\u20137. https:\/\/doi.org\/10.1177\/0883073807302603.","journal-title":"J Child Neurol"},{"issue":"23","key":"4298_CR107","doi-asserted-by":"publisher","first-page":"e2436","DOI":"10.1212\/wnl.0000000000009454","volume":"94","author":"MC Masten","year":"2020","unstructured":"Masten MC, Williams JD, Vermilion J, Adams HR, Vierhile A, Collins A, et al. The CLN3 Disease Staging System: A new tool for clinical research in Batten disease. Neurology. 2020;94(23):e2436\u201340. https:\/\/doi.org\/10.1212\/wnl.0000000000009454.","journal-title":"Neurology"},{"issue":"21","key":"4298_CR108","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1002\/ana.25022","volume":"82","author":"JA Williams","year":"2017","unstructured":"Williams JA, Mink E, J. Developing A Staging System for Juvenile Batten Disease (CLN3 Disease). Ann Neurol. 2017;82(21):S307. https:\/\/doi.org\/10.1002\/ana.25022.","journal-title":"Ann Neurol"},{"issue":"02","key":"4298_CR109","doi-asserted-by":"publisher","first-page":"PS1208","DOI":"10.1055\/s-0032-1307085","volume":"43","author":"C Barkmann","year":"2012","unstructured":"Barkmann C, Moll-Khosrawi P, Kilian D, Kohlsch\u00fctter A, Schulz A. Statistical properties of the jNCL scoring system according to Kohlsch\u00fctter (1988). Neuropediatrics. 2012;43(02):PS1208. https:\/\/doi.org\/10.1055\/s-0032-1307085.","journal-title":"Neuropediatrics"},{"key":"4298_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejpn.2022.03.005","volume":"38","author":"E Wibbeler","year":"2022","unstructured":"Wibbeler E, Nickel M, Schwering C, Schulz A, Mink JW. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample. Eur J Paediatr Neurol. 2022;38:62\u20135. https:\/\/doi.org\/10.1016\/j.ejpn.2022.03.005.","journal-title":"Eur J Paediatr Neurol"},{"key":"4298_CR111","doi-asserted-by":"publisher","unstructured":"Nickel M, Mink JW, Wibbeler E, Schwering C, Schulz A. (2018) The unified batten disease rating scale: an international collaboration testing validation and reliability in an independent cohort of CLN3-Patients. Neuropediatrics. 49: (S 02) FV1180. https:\/\/doi.org\/10.1055\/s-0038-1675912","DOI":"10.1055\/s-0038-1675912"},{"issue":"2","key":"4298_CR112","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.ymgme.2009.10.111","volume":"99","author":"J Mink","year":"2010","unstructured":"Mink J, Kwon JM, Marshall FJ, Adams HR, Rothberg PG, deBlieck EA, et al. The UBDRS predicts rate of JCNL (CLN3) disease progression. Mol Genet Metab. 2010;99(2):S27. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.111.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR113","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.ymgme.2019.11.282","volume":"129","author":"JW Mink","year":"2020","unstructured":"Mink JW, Masten MC, Vermilion J, Adams HR, Vierhile A, Marshall FJ, et al. Cross-sectional and longitudinal quantification of CLN3 disease progression. Mol Genet Metab. 2020;129(2):S109\u201310. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.282.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR114","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ymgme.2009.10.019","volume":"99","author":"H Adams","year":"2010","unstructured":"Adams H, Newhouse NJ, Levy EJ, Mink JW, Kwon JM, Marshall FJ, et al. Visual aid skills and socioeconomic status in children with Batten disease. Mol Genet Metab. 2010;99(2):S8. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.019.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR115","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.ymgme.2019.11.014","volume":"129","author":"HR Adams","year":"2020","unstructured":"Adams HR, Beck C, Bonifacio KP, Marshall FJ, Masten M, Thatcher A, et al. Cross-validation of the Vineland-III with independent assessments of cognition and adaptive skills in CLN3 disease. Mol Genet Metab. 2020;129(2):S17\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.014.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4298_CR116","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ajmg.a.62607","volume":"188","author":"AN Dang Do","year":"2022","unstructured":"Dang Do AN, Thurm AE, Farmer CA, Soldatos AG, Chlebowski CE, O\u2019Reilly JK, et al. Use of the Vineland-3, a measure of adaptive functioning, in CLN3. Am J Med Genet A. 2022;188(4):1056\u201364. https:\/\/doi.org\/10.1002\/ajmg.a.62607.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"4298_CR117","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol. 2013;28(9):1128\u201336. https:\/\/doi.org\/10.1177\/0883073813494813.","journal-title":"J Child Neurol"},{"issue":"Pt 1","key":"4298_CR118","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1365-2788.2001.00288.x","volume":"45","author":"S Lamminranta","year":"2001","unstructured":"Lamminranta S, Aberg LE, Autti T, Moren R, Laine T, Kaukoranta J, et al. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45(Pt 1):8\u201317. https:\/\/doi.org\/10.1046\/j.1365-2788.2001.00288.x.","journal-title":"J Intellect Disabil Res"},{"issue":"Pt 1","key":"4298_CR119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2788.2005.00659.x","volume":"49","author":"ML B\u00e4ckman","year":"2005","unstructured":"B\u00e4ckman ML, Santavuori PR, Aberg LE, Aronen ET. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005;49(Pt 1):25\u201332. https:\/\/doi.org\/10.1111\/j.1365-2788.2005.00659.x.","journal-title":"J Intellect Disabil Res"},{"issue":"S1","key":"4298_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10545-018-0232-x","volume":"41","author":"WF Kuper","year":"2018","unstructured":"Kuper WF, E VA C, Van Eck L, Huijen BC, Van Brussel MB, Van Hasselt PM. The 6-minute walk test reveals early onset of motor decline in CLN3 disease. J Inherit Metab Dis. 2018;41(S1):1\u201336. https:\/\/doi.org\/10.1007\/s10545-018-0232-x.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4298_CR121","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1212\/wnl.0000000000007773","volume":"93","author":"WFE Kuper","year":"2019","unstructured":"Kuper WFE, van Alfen C, van Eck L, Huijgen BCH, Nieuwenhuis EES, van Brussel M, et al. Motor function impairment is an early sign of CLN3 disease. Neurology. 2019;93(3):e293\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000007773.","journal-title":"Neurology"},{"key":"4298_CR122","doi-asserted-by":"publisher","unstructured":"Hofman IL, van der Wal AC, Dingemans KP, Becker AE. Cardiac pathology in neuronal ceroid lipofuscinoses\u2013a clinicopathologic correlation in three patients. Eur J Paediatr Neurol 5 Suppl A. 2001;213\u20137. https:\/\/doi.org\/10.1053\/ejpn.2000.0465.","DOI":"10.1053\/ejpn.2000.0465"},{"key":"4298_CR123","doi-asserted-by":"publisher","unstructured":"Dahlslett TH, Edvardsen I, Skulstatd T. H. The influence of juvenile neuronal ceroid lipofuscinosis on the left ventricle. European Journal of Echocardiography. 2010;11: (suppl_2) ii89-ii119. https:\/\/doi.org\/10.1093\/ejechocard\/jeq144","DOI":"10.1093\/ejechocard\/jeq144"},{"key":"4298_CR124","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/WNL.0b013e31821435bd","volume":"76","author":"JR Ostergaard","year":"2011","unstructured":"Ostergaard JR, Rasmussen TB, M\u00f8lgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011;76:1245\u201351. https:\/\/doi.org\/10.1212\/WNL.0b013e31821435bd.","journal-title":"Neurology"},{"issue":"1","key":"4298_CR125","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijcard.2014.03.159","volume":"174","author":"P Dilaveris","year":"2014","unstructured":"Dilaveris P, Koutagiar I, Aggeli C, Sideris S, Gatzoulis K, Stefanadis C. Severe sinus node dysfunction in a patient with juvenile neuronal ceroid lipofuscinosis. Int J Cardiol. 2014;174(1):143\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2014.03.159.","journal-title":"Int J Cardiol"},{"issue":"11Supplement","key":"4298_CR126","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/S0735-1097(17)35689-9","volume":"69","author":"A Ojo","year":"2017","unstructured":"Ojo A, Harikrishnan P, Olorunfemi O, Iwai S, Raza A, Dutta T, et al. SINUS NODE DYSFUNCTION IN BATTEN DISEASE: A RARE MANIFESTATION OF A RARE DISEASE. J Am Coll Cardiol. 2017;69(11Supplement):2300\u2013. https:\/\/doi.org\/10.1016\/S0735-1097(17)35689-9.","journal-title":"J Am Coll Cardiol"},{"key":"4298_CR127","doi-asserted-by":"publisher","first-page":"846240","DOI":"10.3389\/fneur.2022.846240","volume":"13","author":"MM Handrup","year":"2022","unstructured":"Handrup MM, M\u00f8lgaard H, Andersen BN, Ostergaard JR. Pacemaker Implantation in Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)-A Long-Term Follow-Up Study. Front Neurol. 2022;13:846240. https:\/\/doi.org\/10.3389\/fneur.2022.846240.","journal-title":"Front Neurol"},{"key":"4298_CR128","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3203894\/v1","author":"T Brima","year":"2023","unstructured":"Brima T, Freedman EG, Prinsloo KD, Augustine EF, Adams HR, Wang KH, et al. Assessing the integrity of auditory sensory memory processing in CLN3 disease (Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease)): An auditory evoked potential study of the duration-evoked mismatch negativity (MMN). Res Sq. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3203894\/v1.","journal-title":"Res Sq"},{"issue":"4","key":"4298_CR129","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynel\u00e4","year":"2004","unstructured":"Tyynel\u00e4 J, Cooper JD, Khan MN, Shemilts SJ, Haltia M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 2004;14(4):349\u201357. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00077.x.","journal-title":"Brain Pathol"},{"issue":"2","key":"4298_CR130","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.pediatrneurol.2013.10.013","volume":"50","author":"AM Tokola","year":"2014","unstructured":"Tokola AM, Salli EK, \u00c5berg LE, Autti TH. Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study. Pediatr Neurol. 2014;50(2):158\u201363. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.10.013.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"4298_CR131","doi-asserted-by":"publisher","first-page":"107584","DOI":"10.1016\/j.ymgme.2023.107584","volume":"139","author":"AN Dang Do","year":"2023","unstructured":"Dang Do AN, Baker EH, Farmer CA, Soldatos AG, Thurm AE, Porter FD. Brain proton MR spectroscopy measurements in CLN3 disease. Mol Genet Metab. 2023;139(1):107584. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107584.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"4298_CR132","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3174\/ajnr.A5687","volume":"39","author":"U Roine","year":"2018","unstructured":"Roine U, Roine TJ, Hakkarainen A, Tokola A, Balk MH, Mannerkoski M, et al. Global and Widespread Local White Matter Abnormalities in Juvenile Neuronal Ceroid Lipofuscinosis. AJNR Am J Neuroradiol. 2018;39(7):1349\u201354. https:\/\/doi.org\/10.3174\/ajnr.A5687.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"12","key":"4298_CR133","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3174\/ajnr.A6306","volume":"40","author":"T Roine","year":"2019","unstructured":"Roine T, Roine U, Tokola A, Balk MH, Mannerkoski M, \u00c5berg L, et al. Topological Alterations of the Structural Brain Connectivity Network in Children with Juvenile Neuronal Ceroid Lipofuscinosis. AJNR Am J Neuroradiol. 2019;40(12):2146\u201353. https:\/\/doi.org\/10.3174\/ajnr.A6306.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"4298_CR134","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/jnnp.62.6.622","volume":"62","author":"HM Ruottinen","year":"1997","unstructured":"Ruottinen HM, Rinne JO, Haaparanta M, Solin O, Bergman J, Oikonen VJ, et al. [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry. 1997;62(6):622\u20135. https:\/\/doi.org\/10.1136\/jnnp.62.6.622.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"4298_CR135","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00431-012-1789-2","volume":"171","author":"IL Nestrasil","year":"2012","unstructured":"Nestrasil IL, Sedlacik U, Kohlschutter J, Shapiro A, Schulz E, A. Quantitative brain volumetric analysis in neuronal ceroid lipofuscinoses: A tool to precisely monitor disease progression. Eur J Pediatrics. 2012;171(9):1421\u201331. https:\/\/doi.org\/10.1007\/s00431-012-1789-2.","journal-title":"Eur J Pediatrics"},{"key":"4298_CR136","doi-asserted-by":"publisher","unstructured":"B\u00e4ckman ML, Aberg LE, Aronen ET, Santavuori PR. New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses\u2013a pilot study. Eur J Paediatr Neurol 5 Suppl A. 2001;163\u20136. https:\/\/doi.org\/10.1053\/ejpn.2000.0455.","DOI":"10.1053\/ejpn.2000.0455"},{"issue":"5","key":"4298_CR137","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/wnl.54.5.1069","volume":"54","author":"L Aberg","year":"2000","unstructured":"Aberg L, Liewendahl K, Nikkinen P, Autti T, Rinne JO, Santavuori P. Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology. 2000;54(5):1069\u201374. https:\/\/doi.org\/10.1212\/wnl.54.5.1069.","journal-title":"Neurology"},{"key":"4298_CR138","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajo.2020.07.015","volume":"220","author":"S Dulz","year":"2020","unstructured":"Dulz S, Atiskova Y, Wibbeler E, Wildner J, Wagenfeld L, Schwering C, et al. An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 Disease. Am J Ophthalmol. 2020;220:64\u201371. https:\/\/doi.org\/10.1016\/j.ajo.2020.07.015.","journal-title":"Am J Ophthalmol"},{"issue":"S25","key":"4298_CR139","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/ana.25865","volume":"88","author":"MV Masten","year":"2020","unstructured":"Masten MV, Adams J, Bierhile H, Marshal A, Beck FJ, Augustine CA, Mink EF, J. W. Age-at-Onset and Time-to-Event of Core Features in CLN3 (Batten) Disease. Ann Neurol. 2020;88(S25):S1\u2013280. https:\/\/doi.org\/10.1002\/ana.25865.","journal-title":"Ann Neurol"},{"issue":"2","key":"4298_CR140","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ymgme.2020.12.204","volume":"132","author":"D Phillips","year":"2021","unstructured":"Phillips D, Fernandez V, Nevoret M-L. Characterizing expressive language skills in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective. Mol Genet Metab. 2021;132(2):S86. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.204.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR141","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ymgme.2008.11.093","volume":"96","author":"J Mink","year":"2009","unstructured":"Mink J. Longitudinal studies in Batten disease. Mol Genet Metab. 2009;96(2):S32. https:\/\/doi.org\/10.1016\/j.ymgme.2008.11.093.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4298_CR142","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.ymgme.2019.11.353","volume":"129","author":"S Rastogi","year":"2020","unstructured":"Rastogi S, Conner T, Cook F, Fernandez V, Kirby T. Family survey results of 7 children with atypical neuronal ceroid lipofuscinosis type 2 (CLN2) disease in the United States. Mol Genet Metab. 2020;129(2):S134\u20135. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.353.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4298_CR143","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/dmcn.13623","volume":"59","author":"AA Ockelford","year":"2017","unstructured":"Ockelford AA, R. Neurodegenerative Conditions: Exploring the role of music to enhance speech and cognitive functioning in children with Batten Disease. Dev Med Child Neurol. 2017;59(4):76. https:\/\/doi.org\/10.1111\/dmcn.13623.","journal-title":"Dev Med Child Neurol"},{"key":"4298_CR144","doi-asserted-by":"publisher","unstructured":"Honingh AK, Kruithof YL, Kuper WFE, van Hasselt PM, Sterkenburg PS. Towards Understanding Behaviour and Emotions of Children with CLN3 Disease (Batten Disease): Patterns, Problems and Support for Child and Family. Int J Environ Res Public Health. 2022;19(10). https:\/\/doi.org\/10.3390\/ijerph19105895.","DOI":"10.3390\/ijerph19105895"},{"key":"4298_CR145","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S1090-3798(11)70171-4","volume":"15","author":"A Schulz","year":"2011","unstructured":"Schulz A, Kissenbeck C, Hartmann M, Barkmann C, Kilian D, Richterich A, et al. P05.7 Psychopathology in CLN3 disease: Correlation with disease progression and quality of life. Eur J Pediatr Neurol. 2011;15:S51. https:\/\/doi.org\/10.1016\/S1090-3798(11)70171-4.","journal-title":"Eur J Pediatr Neurol"},{"issue":"5","key":"4298_CR146","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/cch.12993.PMC9541062","volume":"48","author":"M Krantz","year":"2022","unstructured":"Krantz M, Malm E, Darin N, Sofou K, Savvidou A, Reilly C, et al. Parental experiences of having a child with CLN3 disease (juvenile Batten disease) and how these experiences relate to family resilience. Child Care Health Dev. 2022;48(5):842\u201351. https:\/\/doi.org\/10.1111\/cch.12993.","journal-title":"Child Care Health Dev"},{"issue":"5","key":"4298_CR147","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1755-3768.2010.02100.x","volume":"90","author":"LB Augestad","year":"2012","unstructured":"Augestad LB, Klingenberg O, Fosse P. Braille use among Norwegian children from 1967 to 2007: trends in the underlying causes. Acta Ophthalmol. 2012;90(5):428\u201334. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02100.x.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"4298_CR148","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/archdischild-2018-314911","volume":"104","author":"AS Sachdev","year":"2019","unstructured":"Sachdev AS, S. Batten\u2019s disease presenting as visual loss in twins. Arch Dis Child Sep. 2019;104(9):843. https:\/\/doi.org\/10.1136\/archdischild-2018-314911.","journal-title":"Arch Dis Child Sep"},{"issue":"6","key":"4298_CR149","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-2008-1035004","volume":"213","author":"B Neppert","year":"1998","unstructured":"Neppert B, Kemper B. [Juvenile neuronal ceroid lipofuscinosis (Spielmeyer-Vogt disease)]. Klin Monbl Augenheilkd. 1998;213(6):362\u20136. https:\/\/doi.org\/10.1055\/s-2008-1035004.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"4","key":"4298_CR150","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5935\/0004-2749.20170053","volume":"80","author":"E Quagliato","year":"2017","unstructured":"Quagliato E, Rocha DM, Sacai PY, Watanabe SS, Salom\u00e3o SR, Berezovsky A. Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. Arq Bras Oftalmol. 2017;80(4):215\u20139. https:\/\/doi.org\/10.5935\/0004-2749.20170053.","journal-title":"Arq Bras Oftalmol"},{"issue":"3","key":"4298_CR151","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/13816810.2016.1210651","volume":"38","author":"MN Preising","year":"2017","unstructured":"Preising MN, Abura M, J\u00e4ger M, Wassill KH, Lorenz B. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life. Ophthalmic Genet. 2017;38(3):252\u20139. https:\/\/doi.org\/10.1080\/13816810.2016.1210651.","journal-title":"Ophthalmic Genet"},{"issue":"6","key":"4298_CR152","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/bjophthalmol-2015-307320","volume":"100","author":"S Dulz","year":"2016","unstructured":"Dulz S, Wagenfeld L, Nickel M, Richard G, Schwartz R, Bartsch U, et al. Novel morphological macular findings in juvenile CLN3 disease. Br J Ophthalmol. 2016;100(6):824\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307320.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4298_CR153","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/icb.0000000000000200","volume":"10","author":"MS Hansen","year":"2016","unstructured":"Hansen MS, Hove MN, Jensen H, Larsen M, TOMOGRAPHY IN JUVENILE NEURONAL CEROID LIPOFUSCINOSIS. OPTICAL COHERENCE. Retin Cases Brief Rep. 2016;10(2):137\u20139. https:\/\/doi.org\/10.1097\/icb.0000000000000200.","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"4298_CR154","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/13816810.2014.977492","volume":"36","author":"AK Nielsen","year":"2015","unstructured":"Nielsen AK, Drack AV, Ostergaard JR. Cataract and glaucoma development in juvenile neuronal ceroid lipofuscinosis (batten disease). Ophthalmic Genet. 2015;36(1):39\u201342. https:\/\/doi.org\/10.3109\/13816810.2014.977492.","journal-title":"Ophthalmic Genet"},{"issue":"9","key":"4298_CR155","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/s0161-6420(00)00264-5","volume":"107","author":"T Bensaoula","year":"2000","unstructured":"Bensaoula T, Shibuya H, Katz ML, Smith JE, Johnson GS, John SK, et al. Histopathologic and immunocytochemical analysis of the retina and ocular tissues in Batten disease. Ophthalmology. 2000;107(9):1746\u201353. https:\/\/doi.org\/10.1016\/s0161-6420(00)00264-5.","journal-title":"Ophthalmology"},{"issue":"8","key":"4298_CR156","first-page":"1316","volume":"58","author":"S Dulz","year":"2017","unstructured":"Dulz S, Atiskova Y, Hochstein J-N, Wagenfeld L, Nickel M, Sedlacik J, et al. SD-OCT imaging of retinal degeneration in juvenile CLN3 disease - a potential adjunctive tool for global neurodegenerative assessment. Investig Ophthalmol Vis Sci. 2017;58(8):1316.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4298_CR157","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2019.02.020","volume":"94","author":"V Arntsen","year":"2019","unstructured":"Arntsen V, Strandheim J, Helland IB, Sand T, Brodtkorb E. Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan. Epilepsy Behav. 2019;94:59\u201364. https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.020.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"4298_CR158","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.ymgme.2011.11.021","volume":"105","author":"E Augustine","year":"2012","unstructured":"Augustine E, Newhouse N, Adams H, Vierhile A, Kwon J, Marshall F, et al. Epilepsy in Juvenile Neuronal Ceroid Lipofuscinosis is Usually Characterized by Well- Controlled Generalized Tonic-Clonic Seizures. Mol Genet Metab. 2012;105(2):S18\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2011.11.021.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"4298_CR159","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/j.1528-1157.2000.tb04608.x","volume":"41","author":"LE Aberg","year":"2000","unstructured":"Aberg LE, B\u00e4ckman M, Kirveskari E, Santavuori P. Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia. 2000;41(10):1296\u2013302. https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb04608.x.","journal-title":"Epilepsia"},{"issue":"6","key":"4298_CR160","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1528-1157.1999.tb00782.x","volume":"40","author":"L Aberg","year":"1999","unstructured":"Aberg L, Kirveskari E, Santavuori P. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia. 1999;40(6):796\u20139. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb00782.x.","journal-title":"Epilepsia"},{"issue":"s10","key":"4298_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1167.2009.02320.x","volume":"50","author":"J Brodtkorb","year":"2009","unstructured":"Brodtkorb J ES. Clinical Epileptology of Juvenile Neuronal Ceroid Lipofuscinosis. Epilepsia. 2009;50(s10):1\u2013182. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02320.x.","journal-title":"Epilepsia"},{"issue":"6","key":"4298_CR162","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.seizure.2014.02.011","volume":"23","author":"EP Larsen","year":"2014","unstructured":"Larsen EP, Ostergaard JR. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). Seizure. 2014;23(6):429\u201334. https:\/\/doi.org\/10.1016\/j.seizure.2014.02.011.","journal-title":"Seizure"},{"key":"4298_CR163","doi-asserted-by":"publisher","first-page":"1216861","DOI":"10.3389\/fneur.2023.1216861","volume":"14","author":"JR Ostergaard","year":"2023","unstructured":"Ostergaard JR. Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Front Neurol. 2023;14:1216861. https:\/\/doi.org\/10.3389\/fneur.2023.1216861.","journal-title":"Front Neurol"},{"key":"4298_CR164","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.ebr.2021.100427","volume":"15","author":"MD Himmelrich","year":"2021","unstructured":"Himmelrich MD, Pritchard JM, Gutierrez C, Dutta TLM. Paroxysmal sympathetic hyperactivity following status epilepticus in a 22-year-old with Juvenile Neuronal Ceroid Lipofuscinosis: A case report. Epilepsy Behav Rep. 2021;15:100427. https:\/\/doi.org\/10.1016\/j.ebr.2021.100427.","journal-title":"Epilepsy Behav Rep"},{"issue":"2","key":"4298_CR165","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MPG.0000000000001646.28737572","volume":"65","author":"M Romano CvW","year":"2017","unstructured":"Romano CvW M, Hulst J, Broekaert I, Bronsky J, Dall\u2019Oglio L, Mis NF, Hojsak I, Orel R, Papadopoulou A, Schaeppi M, Thapar N, Wilschanski M, Sullivan P, Gottrand F. European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children With Neurological Impairment. J Pediatr Gastroenterol Nutr. 2017;65(2):242\u201364. https:\/\/doi.org\/10.1097\/MPG.0000000000001646.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"4298_CR166","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/SPC.0000000000000154","volume":"9","author":"FH Craig","year":"2015","unstructured":"Craig FH, Bluebond-Langner EM, M. Management of respiratory symptoms in paediatric palliative care. Curr Opin Support Palliat Care. 2015;9(3):217\u201326. https:\/\/doi.org\/10.1097\/SPC.0000000000000154.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"9","key":"4298_CR167","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1651-2227.2012.02680.x.22452449","volume":"101","author":"CH Malcolm","year":"2012","unstructured":"Malcolm CH, Gibson R, Adams F, Anderson S, Forbat G, L. Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families. Acta Paediatr Int J Paediatrics. 2012;101(9):985\u201392. https:\/\/doi.org\/10.1111\/j.1651-2227.2012.02680.x.","journal-title":"Acta Paediatr Int J Paediatrics"},{"key":"4298_CR168","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2016.02.009","volume":"59","author":"LM Lehwald","year":"2016","unstructured":"Lehwald LM, Pappa R, Steward S, de Los Reyes E. Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities. Pediatr Neurol. 2016;59:30\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.02.009.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"4298_CR169","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s0887-8994(00)00138-7","volume":"22","author":"E Kirveskari","year":"2000","unstructured":"Kirveskari E, Partinen M, Salmi T, Sainio K, Telakivi T, H\u00e4m\u00e4l\u00e4inen M, et al. Sleep alterations in juvenile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 2000;22(5):347\u201354. https:\/\/doi.org\/10.1016\/s0887-8994(00)00138-7.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"4298_CR170","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1006\/mgme.1999.2815","volume":"66","author":"T H\u00e4t\u00f6nen","year":"1999","unstructured":"H\u00e4t\u00f6nen T, Kirveskari E, Heiskala H, Sainio K, Laakso ML, Santavuori P. Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy. Mol Genet Metab. 1999;66(4):401\u20136. https:\/\/doi.org\/10.1006\/mgme.1999.2815.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4298_CR171","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13052-016-0285-0","volume":"42","author":"G Silibello","year":"2016","unstructured":"Silibello G, Vizziello P, Gallucci M, Selicorni A, Milani D, Ajmone PF, et al. Daily life changes and adaptations investigated in 154 families with a child suffering from a rare disability at a public centre for rare diseases in Northern Italy. Ital J Pediatr. 2016;42(1):76. https:\/\/doi.org\/10.1186\/s13052-016-0285-0.","journal-title":"Ital J Pediatr"},{"issue":"1","key":"4298_CR172","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0969733017703695","volume":"26","author":"E Olsman","year":"2019","unstructured":"Olsman E, Veneberg B, van Alfen C, Touwen D. The value of metaphorical reasoning in bioethics: An empirical-ethical study. Nurs Ethics. 2019;26(1):50\u201360. https:\/\/doi.org\/10.1177\/0969733017703695.","journal-title":"Nurs Ethics"},{"issue":"5","key":"4298_CR173","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.jpainsymman.2021.12.031","volume":"63","author":"F Benini","year":"2022","unstructured":"Benini F, Papadatou D, Bernad\u00e1 M, Craig F, De Zen L, Downing J, et al. International Standards for Pediatric Palliative Care: From IMPaCCT to GO-PPaCS. J Pain Symptom Manage. 2022;63(5):e529\u201343. https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.12.031.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"4298_CR174","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162. https:\/\/doi.org\/10.1186\/s13023-017-0685-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4298_CR175","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jep.12428","volume":"21","author":"Y Osara","year":"2015","unstructured":"Osara Y, Coakley K, Aisthorpe A, Stembridge A, Quirk M, Splett PL, et al. The role of evidence analysts in creating nutrition management guidelines for inherited metabolic disorders. J Eval Clin Pract. 2015;21(6):1235\u201343. https:\/\/doi.org\/10.1111\/jep.12428.","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"4298_CR176","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/epi.18338","volume":"66","author":"S Beniczky","year":"2025","unstructured":"Beniczky S, Trinka E, Wirrell E, Abdulla F, Al Baradie R, Alonso Vanegas M, et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804\u201323. https:\/\/doi.org\/10.1111\/epi.18338.","journal-title":"Epilepsia"},{"key":"4298_CR177","doi-asserted-by":"publisher","first-page":"811686","DOI":"10.3389\/fneur.2022.811686","volume":"13","author":"A Simonati","year":"2022","unstructured":"Simonati A, Williams RE. Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview. Front Neurol. 2022;13:811686. https:\/\/doi.org\/10.3389\/fneur.2022.811686.","journal-title":"Front Neurol"},{"issue":"7","key":"4298_CR178","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/mds.22515","volume":"24","author":"M Elkay","year":"2009","unstructured":"Elkay M, Silver K, Penn RD, Dalvi A. Dystonic storm due to Batten\u2019s disease treated with pallidotomy and deep brain stimulation. Mov Disord. 2009;24(7):1048\u201353. https:\/\/doi.org\/10.1002\/mds.22515.","journal-title":"Mov Disord"},{"issue":"4","key":"4298_CR179","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ana.10143","volume":"51","author":"S Dhar","year":"2002","unstructured":"Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koeberl DD, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol. 2002;51(4):448\u201366. https:\/\/doi.org\/10.1002\/ana.10143.","journal-title":"Ann Neurol"},{"issue":"9","key":"4298_CR180","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/acn3.625","volume":"5","author":"J Makoukji","year":"2018","unstructured":"Makoukji J, Saadeh F, Mansour KA, El-Sitt S, Al Ali J, Kinarivala N, et al. Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. Ann Clin Transl Neurol. 2018;5(9):1089\u2013103. https:\/\/doi.org\/10.1002\/acn3.625.","journal-title":"Ann Clin Transl Neurol"},{"key":"4298_CR181","doi-asserted-by":"publisher","unstructured":"Maalouf K, Makoukji J, Saab S, Makhoul NJ, Carmona AV, Kinarivala N, et al. Exogenous Flupirtine as Potential Treatment for CLN3 Disease. Cells. 2020;9(8). https:\/\/doi.org\/10.3390\/cells9081872.","DOI":"10.3390\/cells9081872"},{"issue":"5","key":"4298_CR182","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10545-011-9346-0","volume":"34","author":"J Cialone","year":"2011","unstructured":"Cialone J, Augustine EF, Newhouse N, Adams H, Vierhile A, Marshall FJ, et al. Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data. J Inherit Metab Dis. 2011;34(5):1075\u201381. https:\/\/doi.org\/10.1007\/s10545-011-9346-0.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"4298_CR183","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/0883073811410697","volume":"26","author":"HGC Burns","year":"2011","unstructured":"Burns HGC, Chadehumbe Z, M.A. Phenotypic Differences Among Three Siblings With Juvenile Neuronal Ceroid Lipofuscinosis (Batten Disease). J Child Neurol. 2011;26(7):911\u20139. https:\/\/doi.org\/10.1177\/0883073811410697.","journal-title":"J Child Neurol"},{"issue":"4","key":"4298_CR184","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/0883073815600863.PMC4749443","volume":"31","author":"SN Ragbeer","year":"2016","unstructured":"Ragbeer SN, Augustine EF, Mink JW, Thatcher AR, Vierhile AE, Adams HR. Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease): A Pilot Study of Feasibility and Reliability. J Child Neurol. 2016;31(4):481\u20137. https:\/\/doi.org\/10.1177\/0883073815600863.","journal-title":"J Child Neurol"},{"key":"4298_CR185","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1212\/WNL.0b013e3182377e29","volume":"77","author":"J Cialone","year":"2011","unstructured":"Cialone J, Augustine EF, Newhouse N, Vierhile A, Marshall FJ, Mink JW. Quantitative telemedicine ratings in Batten disease: implications for rare disease research. Neurology. 2011;77:1808\u201311. https:\/\/doi.org\/10.1212\/WNL.0b013e3182377e29. PMC3233206.","journal-title":"Neurology"},{"key":"4298_CR186","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S1090-3798(15)30049-0","volume":"19","author":"A Schulz","year":"2015","unstructured":"Schulz A, Simonati A, Laine M, Williams R, Kohlsch\u00fctter A, Nickel M. The DEM-CHILD NCL Patient Database: A tool for the evaluation of therapies in neuronal ceroid lipofuscinoses (NCL). Eur J Pediatr Neurol. 2015;19:S16. https:\/\/doi.org\/10.1016\/S1090-3798(15)30049-0.","journal-title":"Eur J Pediatr Neurol"},{"key":"4298_CR187","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.bbadis.2015.06.018","volume":"1852","author":"IA Cismondi","year":"2015","unstructured":"Cismondi IA, Kohan R, Adams H, Bond M, Brown R, Cooper JD, et al. Guidelines for incorporating scientific knowledge and practice on rare diseases into higher education: neuronal ceroid lipofuscinoses as a model disorder. Biochim Biophys Acta. 2015;1852:2316\u201323. https:\/\/doi.org\/10.1016\/j.bbadis.2015.06.018. (10 Pt B).","journal-title":"Biochim Biophys Acta"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04298-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:45:08Z","timestamp":1781639108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04298-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":187,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4298"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04298-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Each author has completed the ICJME declaration forms, none of whichindicated any competing interests that may have influenced the validity ofthese guidelines. Copies of the completed ICJME forms are available uponreasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}